# Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

Study · id `cardio:ct-nct02009865` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02009865](<https://clinicaltrials.gov/study/NCT02009865>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02009865

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 379 participants.

## Technical summary

Registry record NCT02009865. Randomized; double masking; primary purpose treatment. Start 2013-12-16 (actual); primary completion 2014-12-23 (actual). Results posted on 2016-01-15.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 379 participants (enrolled count; ClinicalTrials.gov record NCT02009865, source copy `cardio:ctgov-nct02009865-2019-09-10`, retrieved 2026-10-31)
- Started: 2013-12-16 (actual) (ClinicalTrials.gov record NCT02009865, source copy `cardio:ctgov-nct02009865-2019-09-10`, retrieved 2026-10-31)
- Primary completion: 2014-12-23 (actual) (ClinicalTrials.gov record NCT02009865, source copy `cardio:ctgov-nct02009865-2019-09-10`, retrieved 2026-10-31)
- Completion: 2014-12-23 (actual) (ClinicalTrials.gov record NCT02009865, source copy `cardio:ctgov-nct02009865-2019-09-10`, retrieved 2026-10-31)
- Results first posted: 2016-01-15 (ClinicalTrials.gov record NCT02009865, source copy `cardio:ctgov-nct02009865-2019-09-10`, retrieved 2026-10-31)
- Countries: United States; Canada; Czechia; Denmark; Hungary; Netherlands; Russia (ClinicalTrials.gov record NCT02009865, source copy `cardio:ctgov-nct02009865-2019-09-10`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02009865-2019-09-10`, retrieved 2026-10-31)

## The registry's words

- Brief title: Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
- Acronym: EVOLVEII
- Condition: Hypertriglyceridemia
- Intervention (Drug): Epanova
- Intervention (Drug): Olive Oil
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 52805bed53ab5c9ad2ca531f9851449482959d6b0f962ef79d97e2d64c045a08
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
